Brief intervention reduces prescription of sodium valproate in women of childbearing age.
Australas Psychiatry
; 31(4): 524-527, 2023 08.
Article
en En
| MEDLINE
| ID: mdl-37035997
ABSTRACT
OBJECTIVE:
Sodium valproate's teratogenicity has prompted increasing restrictions to its use. Our initial audit 2 years prior demonstrated continuing hazardous prescription to women of childbearing age in a New Zealand psychiatric inpatient unit, consistent with nationwide dispensing data.METHOD:
Following a service-wide educational intervention and application of "black box" warnings, we conducted a follow-up audit of valproate prescription in the same inpatient unit by reviewing records of women admitted over a 10-month period (March 2020-January 2021). Results were compared with local and international guidelines, and against data from our initial audit.RESULTS:
Two hundred and sixty-one women of childbearing age were admitted over the sampling period, 26 of whom (10%) were prescribed valproate on discharge. Over three quarters (77%) of these patients had diagnoses other than bipolar affective disorder, valproates only approved psychiatric indication in New Zealand. Following intervention, significant improvements were observed in several key indicators of prescribing quality pregnancy testing, documentation of contraception status, and discussion of teratogenic risk.CONCLUSIONS:
Following intervention, re-audit demonstrated reduced prescription of valproate and improved management of its teratogenic risk in women of childbearing age receiving inpatient psychiatric care. These results demonstrate the value of a systematic approach to improve prescribing practice.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trastorno Bipolar
/
Ácido Valproico
Tipo de estudio:
Guideline
/
Qualitative_research
Límite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Año:
2023
Tipo del documento:
Article